Q-omics provides the consensus-scored ZNF629 profile across patient tissues and cancer cell-line models. ZNF629 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, ZNF629 is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, ZNF629 protein abundance shows 20,876 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BRCA, KIRP, and LSCC as cancer lineages where ZNF629 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF629 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF629 survival associations across molecular data types. ZNF629 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF629 RNA expression–survival associations across cancer types. High ZNF629 expression shows unfavorable associations in SKCM and LGG, but favorable associations in BRCA, KIRC, HNSC and UVM. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for ZNF629 RNA expression.
This table summarizes ZNF629 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF629. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF629 shows higher tumor expression in KIRP, LIHC, BRCA, CHOL, STAD and KICH. The KIRP box plot shows higher ZNF629 RNA expression in tumor versus normal tissue (log2 FC = +1.367, t-test p < 0.001).
This table shows molecular features associated with ZNF629 in patient tissues and cancer cell lines. In patient samples, ZNF629 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF629 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
